Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Lupus (SLE)
FollowWhat is new in Lupus (SLE) research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AcetaminophenPhase 3 · NCT04221477
- Administration of Methylprednisolone + Prednisone + Mycophenolate mofetilPhase 3 · NCT04702256
- Administration of methylprednisolone, paracetamol and dexchlorpheniraminePhase 3 · NCT04702256
- AnifrolumabPhase 3 · NCT05138133
- CenerimodPhase 3 · NCT07201129
- DeucravacitinibPhase 3 · NCT07791199
- DiphenhydraminePhase 3 · NCT04221477
- High-dose CAR-T cells groupPhase 3 · NCT06904729
- IanalumabPhase 3 · NCT06711887
- ianalumab s.c. q12wPhase 3 · NCT05126277
- ianalumab s.c. q4wPhase 3 · NCT05126277
- Low-dose CAR-T cells groupPhase 3 · NCT06904729
- MethylprednisolonePhase 3 · NCT04221477 · NCT05039619
- MMFPhase 3 · NCT04221477
- ObinutuzumabPhase 3 · NCT04221477 · NCT07721363 · NCT05039619 · NCT06265220
- obinutuzumab (RO5072759)Phase 3 · NCT07767188
- Obinutuzumab administrationPhase 3 · NCT04702256
- PrednisonePhase 3 · NCT04221477 · NCT06625671 · NCT05039619
- UpadacitinibPhase 3 · NCT05843643
- Voclosporin（QL1074）Phase 3 · NCT06406205
- MelatoninPhase 2/3 · NCT07721324
- Acetaminophen/paracetamolPhase 2 · NCT05039619
- Active vagus nerve stimulationPhase 2 · NCT06987565
- ADX-097Phase 2 · NCT06419205
- Basic treatmentPhase 2 · NCT06058078
- belantamab mafodotin to the existing stable standard background therapyPhase 2 · NCT07844200
- belimumabPhase 2 · NCT07340463
- Benazepril PillPhase 2 · NCT04486118
- C-CAR168Phase 2 · NCT07729826
- CC-97540Phase 2 · NCT07015983
- cenerimod 4 mgPhase 2 · NCT07266090
- CyclophosphamidePhase 2 · NCT06708845 · NCT07038447 · NCT06375993 · NCT07523542 · NCT07115745 · NCT06897930 · NCT07015983 · NCT06152172 · NCT06265220 · NCT07085104 · NCT06308978 · NCT06434363
- Dapagliflozin 10mg TabPhase 2 · NCT06155604
- DaratumumabPhase 2 · NCT04868838
- Diphenhydramine hydrochloride (HCl)Phase 2 · NCT05039619
- EnvudeucitinibPhase 2 · NCT05966480
- FludarabinePhase 2 · NCT06708845 · NCT07038447 · NCT05508009 · NCT06375993 · NCT07523542 · NCT07115745 · NCT06897930 · NCT07015983 · NCT06152172 · NCT06265220 · NCT07085104 · NCT06308978
- FT819Phase 2 · NCT06308978 · NCT07570862
- GlucocorticoidsPhase 2 · NCT07340463
- HLX79 10mg/kg/Placebo+HLX01Phase 2 · NCT07038382
- HLX79 20mg/kg/Placebo + HLX01Phase 2 · NCT07038382
- HLX79 30mg/kg/placebo+HLX01Phase 2 · NCT07038382
- HSK39297 200mgQDPhase 2 · NCT07363460
- HSK39297 300mgQDPhase 2 · NCT07363460
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletionPhase 2 · NCT07328581
- Lisinopril PillsPhase 2 · NCT04486118
- M5049 high dosePhase 2 · NCT05540327
- M5049 low dosePhase 2 · NCT05540327
- M5049 medium dosePhase 2 · NCT05540327
- Mesenchymal stem cells (MSC)Phase 2 · NCT03673748
- MosunetuzumabPhase 2 · NCT07598396
- Mycophenolate MofetilPhase 2 · NCT05538208 · NCT05039619
- Mycophenolate mofetil (MMF)Phase 2 · NCT07340463
- Obecabtagene autoleucelPhase 2 · NCT07053800
- rapcabtagene autoleucelPhase 2 · NCT06581198
- RY_SW01 cell injectionPhase 2 · NCT06058078
- SHR-2173 InjectionPhase 2 · NCT07229742
- SHR-2173 Injection Blank PreparationPhase 2 · NCT07229742
- SIM0278 injectionPhase 2 · NCT07393451
- SirolimusPhase 2 · NCT04736953
- Standard maintenance therapyPhase 2 · NCT06155604
- TelitaciceptPhase 2 · NCT07340463
- VENT-03Phase 2 · NCT07260877
- VIB4920Phase 2 · NCT05201469
- 626Phase 1/2 · NCT07185269
- APG-2575Phase 1/2 · NCT06182969
- ATGPhase 1/2 · NCT05508009
- Autologous anti-CD19 CAR-T cells, intravenous single infusion at protocol-defined dose level (1 x 10^6 or 3 x 10^6 CAR-positive viable T cells/kg).Phase 1/2 · NCT07523542
- Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood CenterPhase 1/2 · NCT07659704
- AZD0120Phase 1/2 · NCT06897930
- CABA-201Phase 1/2 · NCT06121297
- CART19Phase 1/2 · NCT06839976
- CD19 CAR-T cellsPhase 1/2 · NCT07233642 · NCT06585514 · NCT07331467
- CD19-BCMA CAR-T cells infusionPhase 1/2 · NCT06947460
- CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 SystemPhase 1/2 · NCT05508009
- CRC01Phase 1/2 · NCT07364396
- Cyclophosphamide 100 mg/KgPhase 1/2 · NCT05508009
- Cyclophosphamide 1200 mg/KgPhase 1/2 · NCT05508009
- Dapagliflozin (10Mg Tab) along with standard medical therapyPhase 1/2 · NCT07678203
- DB-2304Phase 1/2 · NCT06625671
- Fludarabine phosphatePhase 1/2 · NCT06434363
- Fludarabine, CyclophosphamidePhase 1/2 · NCT06557265
- high dose GR1603 in phase ⅡPhase 1/2 · NCT06015230
- high dose GR1603 in phaseⅠbPhase 1/2 · NCT06015230
- Injection of MSC303Phase 1/2 · NCT07000292
- Kidney TransplantPhase 1/2 · NCT05508009
- low dose GR1603 in phase ⅠbPhase 1/2 · NCT06015230
- low dose GR1603 in phase ⅡPhase 1/2 · NCT06015230
- MB-CART19.1Phase 1/2 · NCT06189157
- MelphalanPhase 1/2 · NCT05508009
- NKX019Phase 1/2 · NCT06557265 · NCT06518668
- PovetaciceptPhase 1/2 · NCT05732402
- Proteinuria QuantificationPhase 1/2 · NCT07678203
- Recombinant Humanized Monoclonal Antibody MIL62 InjectionPhase 1/2 · NCT07044115
- RituximabPhase 1/2 · NCT06676631 · NCT05508009 · NCT06265220
- TafasitamabPhase 1/2 · NCT06434363
- Tafasitamab and NK cellsPhase 1/2 · NCT06434363
- Total Body IrradiationPhase 1/2 · NCT05508009
- TranspoCART19Phase 1/2 · NCT07799116
- umbilical cord blood CD19-BCMA CAR-T cells infusionPhase 1/2 · NCT06947473
- AB-101Phase 1 · NCT06265220
- ADI-001Phase 1 · NCT06375993
- ALLO-329Phase 1 · NCT07085104
- AlnuctamabPhase 1 · NCT07219563
- AnticoagulationPhase 1 · NCT04976465
- BCMA/CD70 CAR-T cellsPhase 1 · NCT07318259
- BendamustinePhase 1 · NCT06308978
- BMS-986515Phase 1 · NCT07115745
- BMS-986553Phase 1 · NCT07873931
- CAR-T TherapyPhase 1 · NCT07031713
- CC312Phase 1 · NCT07177911 · NCT07193810
- CD19 Universal CAR-T cellsPhase 1 · NCT06691152
- CevostamabPhase 1 · NCT07629583
- CLN-978Phase 1 · NCT06613360
- CNTY-101Phase 1 · NCT06255028
- CTX112Phase 1 · NCT06925542
- Cyclophosphamide LDPhase 1 · NCT06518668
- FKC289Phase 1 · NCT06285279
- HB2198Phase 1 · NCT07491900
- HC022Phase 1 · NCT07306585
- HN2301 injectionPhase 1 · NCT06801119
- IASO-782 injectionPhase 1 · NCT07483346
- IL-2Phase 1 · NCT06255028
- KITE-363Phase 1 · NCT07038447
- KN5501 cell injectionPhase 1 · NCT07358988
- KYV-101Phase 1 · NCT06152172
- LMY-922Phase 1 · NCT07729995
- LUCAR-G79D T cellsPhase 1 · NCT07331272
- Lymphodepleting ChemotherapyPhase 1 · NCT06255028 · NCT07855302
- MC-1-50Phase 1 · NCT06892145
- NK 010 or NK042Phase 1 · NCT06676631
- NTR1011Phase 1 · NCT07237659
- OdronextamabPhase 1 · NCT06975787
- PIT565Phase 1 · NCT06335979
- PTOC1Phase 1 · NCT07403097
- QT-019CPhase 1 · NCT07315087
- SC291Phase 1 · NCT06294236
- single dose of UC-MSCsPhase 1 · NCT06737380
- SNUH-CD19-CAR-T CellsPhase 1 · NCT07855302
- STK-009Phase 1 · NCT06544330
- SurovatamigPhase 1 · NCT07201558
- SYNCAR-001Phase 1 · NCT06544330
- TocilizumabPhase 1 · NCT07115745 · NCT07629583
- UB-VV410Phase 1 · NCT07109986
- VonsetamigPhase 1 · NCT06975787
- Without AnticoagulationPhase 1 · NCT04976465
- YTS109 cellPhase 1 · NCT07104721 · NCT07236762 · NCT07123519
- zamtocabtagene autoleucelPhase 1 · NCT06708845
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMAEarly phase 1 · NCT07274059
- Arnovie101 Infusion IntravenousEarly phase 1 · NCT07629596
- AXA-NK02Early phase 1 · NCT07412210
- CD19 CAR-γδ T cellEarly phase 1 · NCT07535138
- CD19/BCMA CAR T-cellsEarly phase 1 · NCT07266337
- CD19/BCMA Lupus Nephritis Targeted CAR T-cells injectionEarly phase 1 · NCT06785519
- KN5601Early phase 1 · NCT07490041
- Metabolically Armed CD19 CAR-T cellsEarly phase 1 · NCT06711146
- Normal salineEarly phase 1 · NCT06485648
- ONT01 is a small molecule CD11b modulator.Early phase 1 · NCT07107659
- PRG-1801Early phase 1 · NCT06497387
- PRG-2311Early phase 1 · NCT06497361
- RD06-05 CAR-T Cell InjectionEarly phase 1 · NCT07596680
- RD06-05 CART Cell InfusionEarly phase 1 · NCT07674147
- Umbilical cord mesenchymal stem cellsEarly phase 1 · NCT06485648
Closest to patients
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisA Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisDOM Centro de Reumatología · Buenos Aires, Argentina + 69 more hospitalsPhase 3Primary completion 2024
- Effect of Melatonin Administration on Systemic Lupus Erythematosus PatientsEffect of Melatonin Administration on Systemic Lupus Erythematosus PatientsDepartment of Rheumatology Ain Shams University hospitals · Cairo, EgyptPhase 2/3Results expected 2026
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisResearch Site · CABA, Argentina + 146 more hospitalsPhase 3Results expected 2027
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study.
Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study.
PLoS medicine
PubMed · PMID 42976215Publication
Reducing glucocorticoid burden in lupus with omega-3 fatty acids: docosahexaenoic acid augments prednisone efficacy in maintaining cyclophosphamide-induced remission of preclinical lupus nephritis.
Reducing glucocorticoid burden in lupus with omega-3 fatty acids: docosahexaenoic acid augments prednisone efficacy in maintaining cyclophosphamide-induced remission of preclinical lupus nephritis.
Autoimmunity
PubMed · PMID 42733187Review
Association of Vitamin D Deficiency With Cardiometabolic and Renal Outcomes in Patients With Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
Association of Vitamin D Deficiency With Cardiometabolic and Renal Outcomes in Patients With Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
Cureus
PubMed · PMID 42668756
Find fellow researchers
Groups with active Lupus (SLE) work.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska University Hospital
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Peking Union Medical College Hospital
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Assistance Publique – Hôpitaux de Paris
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang Chinese Medical University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it